Development of CRISPR/Cas13a-based assays for the diagnosis of Schistosomiasis.

ABSTRACT:

Background

Schistosomiasis is a disease that significantly impacts human health in the developing world. Effective diagnostics are urgently needed for improved control of this disease. CRISPR-based technology has rapidly accelerated the development of a revolutionary and powerful diagnostics platform, resulting in the advancement of a class of ultrasensitive, specific, cost-effective and portable diagnostics, typified by applications in COVID-19/cancer diagnosis.

Methods

We developed CRISPR-based diagnostic platform SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) for the detection of Schistosoma japonicum and S. mansoni by combining recombinase polymerase amplification (RPA) with CRISPR-Cas13a detection, measured via fluorescent or colorimetric readouts. We

SUBMITTER: MacGregor SR 

PROVIDER: S-EPMC10382885 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature